Progression of Paper-Based Point-of-Care Testing toward Being an Indispensable Diagnostic Tool in Future Healthcare.

Point-of-care (POC) diagnostics in particular focuses on the timely identification of harmful conditions close to the patients' needs. For future healthcare these diagnostics could be an invaluable tool especially in a digitalized or telemedicine-based system. However, while paper-based POC tests, with the most prominent example being the lateral flow assay (LFA), have been especially successful due to their simplicity and timely response, the COVID-19 pandemic highlighted their limitations, such as low sensitivity and ambiguous responses.

Recovery of DNA from fired and unfired cartridge casings: comparison of two DNA collection methods.

For over 10 years, various studies have attempted to increase the recovery of DNA from ammunition by modifying the DNA collection, extraction, purification, and amplification procedures, with varying levels of success. This study focused on the "soaking" method of Montpetit & O'Donnell [1] and the "rinse-and-swab" method of Bille et al. [2].

Microfluidic flow-injection aptamer-based chemiluminescence platform for sulfadimethoxine detection.

Gold nanoparticle-catalyzed chemiluminescence (CL) of luminol is an attractive alternative to strategies relying on enzymes, as their aggregation leads to significantly enhanced CL signals. Consequently, analytes disturbing such aggregation will lead to an easy-to-quantify weakening of the signal. Based on this concept, a homogeneous aptamer-based assay for the detection of sulfadimethoxine (SDM) has been developed as a microfluidic CL flow-injection platform.

Next generation luminol derivative as powerful benchmark probe for chemiluminescence assays.

Chemiluminescence (CL) provides outstanding analytical performance due to its independence from external light sources, background-free nature and exceptional sensitivity and selectivity. Yet, ultra-sensitive (bio)analysis is impeded by low hydrophilicity, poor quantum yields, fast kinetics or instability of most CL reagents such as luminol, acridinium esters, dioxetanes or peroxyoxalic derivatives. Photophysical studies show that m-carboxy luminol overcomes these limitations as its hydrophilic design provides a 5-fold increase in relative quantum yield resulting in superior performance in HO-dependent bioassays with 18-fold higher sensitivity for the quantification of its co-reactant HO, and 5-times lower detection limits for the luminophore.

Highly sensitive interleukin 6 detection by employing commercially ready liposomes in an LFA format.

Recent years have confirmed the ubiquitous applicability of lateral flow assays (LFA) in point-of-care testing (POCT). To make this technology available for low abundance analytes, strategies towards lower limits of detections (LOD), while maintaining the LFA's ease of use, are still being sought. Here, we demonstrate how liposomes can significantly improve the LOD of traditional gold nanoparticle (AuNP)-based assays while fully supporting a ready-to-use system for commercial application.